“The existing problem has uncovered some structural weaknesses inside the EU’s medicines supply chain as well as a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides stated. She suggested that provide chain challenges be dealt with in an EU pharmaceutical approach envisioned to be introduced by the end of th